Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravesical bacillus Calmette-Guérin and second primary malignancies.

P Guinan1, S Brosman, J DeKernion

  • 1Urologic Services of Cook County Hospital, Chicago, Illinois.

Urology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breeding for sustainability: Development of an index to reduce greenhouse gas in dairy cattle.

Animal : an international journal of animal bioscience·2025
Same author

Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients: A Real-World Evidence Study in Spain.

Actas dermo-sifiliograficas·2023
Same author

Clinical Unmet Needs and Treatment Patterns of Paediatric Psoriasis Patients: A Real-World Evidence Study in Spain.

Actas dermo-sifiliograficas·2023
Same author

Outbreak of SARS-CoV-2 in a teenage discotheque in Northern Ireland-November 2021.

Public health·2022
Same author

Adverse reactions following transfusion of blood components, with a focus on some rare reactions: Reports to the International Haemovigilance Network Database (ISTARE) in 2012-2016.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2022
Same author

Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Intravesical bacillus Calmette-Guérin (BCG) therapy for bladder cancer does not appear to increase the risk of secondary cancers. Current evidence suggests BCG

Area of Science:

  • Oncology
  • Urology
  • Immunotherapy

Background:

  • Intravesical bacillus Calmette-Guérin (BCG) is a standard treatment for high-risk superficial bladder cancer.
  • Concerns exist regarding the potential for BCG therapy to increase the incidence of second primary malignancies.
  • Evaluating the safety profile of BCG, particularly long-term effects, is crucial for patient management.

Purpose of the Study:

  • To investigate whether intravesical BCG therapy is associated with an increased risk of developing second primary malignancies in patients treated for carcinoma in situ of the urinary bladder.
  • To assess the overall risk-benefit profile of intravesical BCG in managing superficial bladder cancer.

Main Methods:

  • Retrospective review of medical records.
  • Analysis of data from 153 patients treated with intravesical BCG for bladder carcinoma in situ.

Related Experiment Videos

  • Comparison of malignancy incidence in treated patients against established cancer risk data (implied).

    • Main Results:

    • The available evidence suggests that intravesical BCG therapy does not elevate the occurrence of second primary malignancies.
    • The study indicates that the benefits of BCG for high-risk superficial bladder cancer patients likely outweigh the known risks.

    Conclusions:

    • Intravesical BCG therapy is not associated with an increased incidence of second primary malignancies based on current data.
    • The therapeutic advantages of BCG for high-risk superficial bladder cancer patients are considered to outweigh its disadvantages.
    • Further investigation into this question is warranted, but current findings support the use of BCG.